Advanced Medical Solutions Group plc
("AMS", the "Company"
or the "Group")
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in
tissue-healing technologies,
announces that it was
notified on 10 October 2024 that on the same day
Grahame Cook, Non-Executive Director, purchased 48,864
ordinary shares of 5p each ("Ordinary Shares") at a price of
205.25p per Ordinary Share.
The notification below, made in
accordance with the requirements of the EU Market Abuse Regulation,
provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1.
|
Details of the person discharging
managerial responsibilities/person closely
associated
|
|
a)
|
Name: Grahame
Cook
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status:
Non-Executive Director
|
|
b)
|
Initial
notification/Amendment: Initial Notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name:
Advanced Medical Solutions Group plc
|
|
b)
|
LEI: 213800HJP6OWOSZI1L74
|
4.
|
Details of the transaction(s): section
to be repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the
financial instrument, type of instrument: Ordinary Shares of
5p
Identification code:
GB0004536594
|
|
b)
|
Nature of the
transactions:
· Purchase of Ordinary Shares
|
|
c)
|
Price(s) and
volume(s):
|
Price(s)
|
Volume(s)
|
|
Purchase of shares at
205.25p per share
|
48,864
|
|
|
d)
|
Aggregated
information:
N/A
|
|
e)
|
Date of the
transaction: 10/10/2024
|
|
f)
|
Place of the
transaction: London Stock Exchange, AIM Market (XLON)
|
- End -
For
further information, please visit www.admedsol.com
or
contact:
|
Advanced Medical Solutions Group plc
|
Tel: +44
(0) 1606 545508
|
|
Chris Meredith, Chief Executive
Officer
Eddie Johnson, Chief Financial
Officer
Michael King, Investor
Relations
|
|
|
|
|
|
ICR
Consilium
|
Tel: +44
(0) 20 3709 5700
|
|
Mary-Jane Elliott
/ Lucy Featherstone
|
AMS@consilium-comms.com
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker)
|
Tel: +44
(0) 20 7597 5970
|
|
Gary Clarence / David
Anderson
|
|
|
HSBC Bank plc (Broker)
|
Tel: 44
(0) 20 7991 8888
|
|
Joe Weaving / Stephanie
Cornish
|
|
About Advanced Medical Solutions Group plc
-
see www.admedsol.com
AMS is a world-leading independent
developer and manufacturer of innovative tissue-healing technology,
focused on quality outcomes for patients and value for payers. AMS
has a wide range of surgical products including tissue adhesives,
sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver
alginates, alginates and foams through its ActivHeal® brand as well
as under white label. Since 2019, the Group has made seven
acquisitions: Sealantis, an Israeli developer of innovative
internal sealants, Biomatlante, a French developer and manufacturer
of surgical biomaterials, Raleigh, a leading UK coater and
converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish
tissue adhesives specialist, Syntacoll, a German specialist in
collagen-based absorbable surgical implants and Peters Surgical, a
global provider of specialty surgical sutures, mechanical
haemostasis and internal cyanoacrylate devices.
AMS's products, manufactured in the
UK, Germany, France, the Netherlands, Thailand, India, the Czech
Republic and Israel, are sold globally via a network of
multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France,
Poland, Benelux, India, the Czech Republic and Russia. The Group
has R&D innovation hubs in the UK, Ireland, Germany, France and
Israel. Established in 1991, the Group has more than 1,500
employees. For more information, please see
www.admedsol.com.